Drug Patents Expiring in 2037

1. List of Adlarity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307379 CORIUM Donepezil transdermal delivery system
Jul, 2037

(14 years from now)

US9993466 CORIUM Donepezil transdermal delivery system
Jul, 2037

(14 years from now)

US10300025 CORIUM Donepezil transdermal delivery system
Jul, 2037

(14 years from now)

US11103463 CORIUM Methods for treating alzheimer's disease with donepezil transdermal system
Jul, 2037

(14 years from now)

US10016372 CORIUM Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Jul, 2037

(14 years from now)

Do you want to check out ADLARITY patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Mar 11, 2025

Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2022

Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

ADLARITY family patents

26

United States

10

Japan

8

Korea, Republic of

5

China

5

Canada

5

Australia

5

European Union

2

Russia

2

Singapore

2

Mexico

2. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2037

(13 years from now)

Do you want to check out AIRDUO DIGIHALER patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

3. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529362 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant
Jun, 2037

(14 years from now)

US10624911 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant
Jun, 2037

(14 years from now)

Do you want to check out AKYNZEO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 2022-04-19

Market Authorisation Date: 19 April, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's patent expiration?
More Information on Dosage

AKYNZEO family patents

3

United States

3

European Union

2

Japan

1

Uruguay

1

Spain

1

Philippines

1

Moldova, Republic of

1

Denmark

1

RS

1

Poland

1

China

1

Brazil

1

Canada

1

Ukraine

1

Morocco

1

Singapore

1

Argentina

EA

1

EA

1

Croatia

1

Korea, Republic of

1

Cyprus

1

Peru

1

Chile

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

Australia

1

Ecuador

1

South Africa

1

Colombia

1

Lithuania

1

Slovenia

4. List of Amzeeq drug patents

Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398641 JOURNEY Compositions and methods for treating rosacea and acne
Sep, 2037

(14 years from now)

US10849847 JOURNEY Compositions and methods for treating rosacea and acne
Sep, 2037

(14 years from now)

Do you want to check out AMZEEQ patents from before 2022?

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of AMZEEQ before it's patent expiration?
More Information on Dosage

AMZEEQ family patents

7

United States

1

Canada

1

Mexico

5. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2037

(13 years from now)

Do you want to check out ARMONAIR DIGIHALER patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

6. List of Atorvaliq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11369567 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(14 years from now)

Do you want to check out ATORVALIQ patents from before 2022?

Drugs and Companies using ATORVASTATIN CALCIUM ingredient

Market Authorisation Date: 01 February, 2023

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

7. List of Auvi-q drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688244 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children
Dec, 2037

(14 years from now)

US10842938 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children
Dec, 2037

(14 years from now)

Do you want to check out AUVI-Q patents from before 2022?

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method of treating an allergic reaction using an auto-injector

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

6

United States

1

Canada

1

Japan

1

Australia

1

European Union

8. List of Azstarys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

Do you want to check out AZSTARYS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 7, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 2025-05-07

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL

More Information on Dosage

AZSTARYS family patents

16

United States

2

Israel

2

Australia

1

New Zealand

1

Korea, Republic of

1

China

1

Brazil

1

Canada

1

Mexico

1

Japan

1

European Union

9. List of Bludigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927258 PROVEPHARM SAS Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(14 years from now)

US11499050 PROVEPHARM SAS NA
Dec, 2037

(14 years from now)

Do you want to check out BLUDIGO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 8, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: 2026-07-08

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BLUDIGO family patents

3

United States

2

India

1

European Union

10. List of Brukinsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11591340 BEIGENE NA
Aug, 2037

(14 years from now)

Do you want to check out BRUKINSA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Orphan Drug Exclusivity (ODE) Sep 14, 2028
New Indication (I) Sep 14, 2024

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 2023-11-15

Market Authorisation Date: 14 November, 2019

Treatment: For the treatment of patients with waldenstrom's macroglobulinemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with...

Dosage: CAPSULE;ORAL

More Information on Dosage

BRUKINSA family patents

7

United States

2

China

2

Israel

2

Japan

2

Australia

1

Korea, Republic of

IB

1

IB

1

Brazil

1

South Africa

1

Canada

1

Taiwan

1

Singapore

EA

1

EA

1

Mexico

1

European Union

11. List of Cabometyx drug patents

Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
Apr, 2037

(13 years from now)

Do you want to check out CABOMETYX patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

CABOMETYX family patents

19

United States

1

Russia

1

China

1

Canada

1

Morocco

1

European Union

12. List of Calcium Gluconate In Sodium Chloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130646 HQ SPCLT PHARMA Calcium gluconate solutions in flexible containers
Jul, 2037

(14 years from now)

US10342813 HQ SPCLT PHARMA Calcium gluconate solutions in flexible containers
Jul, 2037

(14 years from now)

Do you want to check out CALCIUM GLUCONATE IN SODIUM CHLORIDE patents from before 2022?

Drugs and Companies using CALCIUM GLUCONATE ingredient

Market Authorisation Date: 29 October, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALCIUM GLUCONATE IN SODIUM CHLORIDE family patents

3

United States

13. List of Cequa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(13 years from now)

Do you want to check out CEQUA patents from before 2022?

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 14 August, 2018

Treatment: NA

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

CEQUA family patents

8

United States

2

Japan

2

Australia

1

Korea, Republic of

1

China

1

Russia

1

Israel

1

Brazil

1

South Africa

1

Canada

1

Singapore

1

Mexico

1

European Union

14. List of Definity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US11529431 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US11266750 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents
May, 2037

(13 years from now)

Do you want to check out DEFINITY patents from before 2022?

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

DEFINITY family patents

19

United States

4

Israel

3

Korea, Republic of

3

China

3

Taiwan

3

Japan

2

Canada

2

Brazil

2

Singapore

EA

2

EA

2

Mexico

2

Australia

2

European Union

15. List of Dextenza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458041 OCULAR THERAPEUTIX Punctal plug and bioadhesives
Nov, 2037

(14 years from now)

Do you want to check out DEXTENZA patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

DEXTENZA family patents

3

United States

16. List of Drizalma Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11202772 SUN PHARM Duloxetine sprinkles
Apr, 2037

(13 years from now)

US10959982 SUN PHARM Duloxetine sprinkles
Apr, 2037

(13 years from now)

US10413525 SUN PHARM Duloxetine sprinkles
Apr, 2037

(13 years from now)

US9839626 SUN PHARM Duloxetine sprinkles
Apr, 2037

(13 years from now)

Do you want to check out DRIZALMA SPRINKLE patents from before 2022?

Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 July, 2019

Treatment: NA

Dosage: CAPSULE, DELAYED REL PELLETS;ORAL

More Information on Dosage

DRIZALMA SPRINKLE family patents

6

United States

1

India

1

European Union

17. List of Esbriet drug patents

ESBRIET's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
Mar, 2037

(13 years from now)

Do you want to check out ESBRIET patents from before 2022?

Drugs and Companies using PIRFENIDONE ingredient

Market Authorisation Date: 11 January, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ESBRIET before it's patent expiration?
More Information on Dosage

ESBRIET family patents

4

United States

2

China

2

Japan

2

European Union

1

Korea, Republic of

1

Poland

1

Spain

1

Israel

1

Canada

1

Argentina

1

Mexico

1

Australia

18. List of Evekeo Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441554 ARBOR PHARMS LLC Oral amphetamine composition
Mar, 2037

(13 years from now)

US11160772 ARBOR PHARMS LLC Oral amphetamine composition
Mar, 2037

(13 years from now)

Do you want to check out EVEKEO ODT patents from before 2022?

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

EVEKEO ODT family patents

4

United States

19. List of Fintepla drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10947183

(Pediatric)

ZOGENIX INC Fenfluramine compositions and methods of preparing the same
Jun, 2037

(14 years from now)

US11406606 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(14 years from now)

US11040018 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(14 years from now)

US10603290 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(14 years from now)

Do you want to check out FINTEPLA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 25, 2029
New Product (NP) Jun 25, 2023
New Indication (I) Mar 25, 2025
Pediatric Exclusivity (PED) Dec 25, 2027

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with dravet syndrome; Use of fenfluramine at reduced amounts with stiripentol for the treatment of seiz...

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's patent expiration?
More Information on Dosage

FINTEPLA family patents

9

United States

2

Russia

2

Israel

2

Taiwan

2

Japan

2

Australia

1

New Zealand

1

Korea, Republic of

IB

1

IB

1

China

1

South Africa

1

Canada

1

Singapore

1

Mexico

1

European Union

20. List of Firdapse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10626088 CATALYST PHARMS Determining degradation of 3,4-diaminopyridine
Feb, 2037

(13 years from now)

Do you want to check out FIRDAPSE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 28, 2023
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Patient Population (NPP) Sep 29, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: 2022-11-28

Market Authorisation Date: 28 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

FIRDAPSE family patents

3

United States

21. List of Fleqsuvy drug patents

Can you believe FLEQSUVY received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(14 years from now)

US11324696 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(14 years from now)

Do you want to check out FLEQSUVY patents from before 2022?

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of FLEQSUVY before it's patent expiration?
More Information on Dosage

FLEQSUVY family patents

11

United States

1

China

1

Canada

1

European Union

22. List of Fluorescein Sodium And Benoxinate Hydrochloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10293047 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(14 years from now)

US10632197 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(14 years from now)

US10842872 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(14 years from now)

Do you want to check out FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE patents from before 2022?

Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient

Market Authorisation Date: 09 March, 2020

Treatment: Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic ane...

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE family patents

5

United States

1

China

1

Canada

1

European Union

23. List of Galafold drug patents

GALAFOLD's oppositions filed in EPO
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234972 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(13 years from now)

US10076514 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(13 years from now)

Do you want to check out GALAFOLD patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023
Orphan Drug Exclusivity (ODE) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's patent expiration?
More Information on Dosage

GALAFOLD family patents

6

United States

3

Taiwan

2

Korea, Republic of

2

China

2

Japan

1

European Union

24. List of Giapreza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219662 LA JOLLA PHARMA Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Jan, 2037

(13 years from now)

Do you want to check out GIAPREZA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 2021-12-21

Market Authorisation Date: 21 December, 2017

Treatment: Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's patent expiration?
More Information on Dosage

GIAPREZA family patents

7

United States

1

Korea, Republic of

1

Brazil

1

Canada

1

Taiwan

1

Japan

1

Australia

1

European Union

25. List of Gloperba drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226423 ROMEG Colchicine drug-to-drug interactions
Dec, 2037

(14 years from now)

Do you want to check out GLOPERBA patents from before 2022?

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of GLOPERBA before it's patent expiration?
More Information on Dosage

26. List of Goprelto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933060 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10016407 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US11040032 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10231961 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10857095 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10894012 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10987347 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10973811 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US9867815 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10149843 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10420760 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10413505 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

Do you want to check out GOPRELTO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 2021-12-14

Market Authorisation Date: 14 December, 2017

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or ren...

Dosage: SOLUTION;NASAL

More Information on Dosage

GOPRELTO family patents

14

United States

27. List of Hemady drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304961 DEXCEL PHARMA Compositions comprising dexamethasone
Dec, 2037

(14 years from now)

US10537585 DEXCEL PHARMA Compositions comprising dexamethasone
Dec, 2037

(14 years from now)

Do you want to check out HEMADY patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 3, 2026

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 03 October, 2019

Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product

Dosage: TABLET;ORAL

More Information on Dosage

HEMADY family patents

2

United States

1

Israel

28. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

Do you want to check out INGREZZA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 2021-04-11

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; Method of administering valbenazine while avoiding concomitant use of ...

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

INGREZZA family patents

25

United States

11

Japan

8

Australia

7

Korea, Republic of

6

China

6

Philippines

6

Canada

EA

6

EA

6

Mexico

4

Singapore

1

Malaysia

29. List of Inlyta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(13 years from now)

Do you want to check out INLYTA patents from before 2022?

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's patent expiration?
More Information on Dosage

INLYTA family patents

8

United States

2

Japan

1

New Zealand

1

Korea, Republic of

1

China

1

Russia

1

Hong Kong

1

Philippines

1

Malaysia

1

Israel

1

Canada

1

Taiwan

1

Mexico

1

Australia

1

European Union

30. List of Katerzia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959991 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US11484498 AZURITY NA
Oct, 2037

(14 years from now)

US11471409 AZURITY NA
Oct, 2037

(14 years from now)

US11364230 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10894039 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10952998 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10695329 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

Do you want to check out KATERZIA patents from before 2022?

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: Angina pectoris; Angina; A method of treating coronary artery disease; A method of treating hypertension; Treatment of hypertension; Method of treating hypertension

Dosage: SUSPENSION;ORAL

How can I launch a generic of KATERZIA before it's patent expiration?
More Information on Dosage

KATERZIA family patents

14

United States

3

European Union

2

Canada

1

China

1

Spain

1

Japan

31. List of Korlym drug patents

KORLYM Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10151763 CORCEPT THERAP Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
Jan, 2037

(13 years from now)

US10195214 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(14 years from now)

US10842800 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(14 years from now)

Do you want to check out KORLYM patents from before 2022?

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

How can I launch a generic of KORLYM before it's patent expiration?
More Information on Dosage

KORLYM family patents

13

United States

2

Korea, Republic of

2

Israel

2

Canada

2

Singapore

2

Mexico

2

Japan

2

Australia

2

European Union

1

China

1

Spain

32. List of Krazati drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10689377 MIRATI THERAPS KRas G12C inhibitors
May, 2037

(13 years from now)

Do you want to check out KRAZATI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 12, 2027
Orphan Drug Exclusivity (ODE) Dec 12, 2029

Drugs and Companies using ADAGRASIB ingredient

NCE-1 date: 2026-12-12

Market Authorisation Date: 12 December, 2022

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...

Dosage: TABLET;ORAL

More Information on Dosage

KRAZATI family patents

7

United States

2

Japan

2

European Union

1

Korea, Republic of

1

China

1

Philippines

1

Chile

1

South Africa

1

Israel

1

Ukraine

1

Taiwan

1

Singapore

1

Brazil

1

Canada

1

Colombia

EA

1

EA

1

Australia

33. List of Lexette drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857159

(Pediatric)

MAYNE PHARMA Halobetasol foam composition and method of use thereof
May, 2037

(14 years from now)

Do you want to check out LEXETTE patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Aug 18, 2024

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of LEXETTE before it's patent expiration?
More Information on Dosage

34. List of Lonsurf drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(13 years from now)

US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(13 years from now)

Do you want to check out LONSURF patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 22, 2026

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Market Authorisation Date: 22 September, 2015

Treatment: Method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf

Dosage: TABLET;ORAL

How can I launch a generic of LONSURF before it's patent expiration?
More Information on Dosage

LONSURF family patents

4

United States

3

Japan

2

Korea, Republic of

1

New Zealand

1

Russia

1

South Africa

1

Ukraine

1

Taiwan

1

Morocco

1

Australia

1

European Union

35. List of Lupkynis drug patents

LUPKYNIS Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11622991 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(14 years from now)

US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(14 years from now)

Do you want to check out LUPKYNIS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 2025-01-22

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage

LUPKYNIS family patents

5

United States

2

Japan

1

Korea, Republic of

1

China

IB

1

IB

1

Russia

1

Chile

1

Canada

1

South Africa

1

Brazil

1

Australia

1

European Union

36. List of Myfembree drug patents

MYFEMBREE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(14 years from now)

Do you want to check out MYFEMBREE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
M (M) Jan 27, 2026
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

16

United States

7

European Union

4

Japan

4

Australia

3

Canada

3

Morocco

3

Argentina

EA

3

EA

3

Israel

2

China

2

Brazil

2

New Zealand

2

Mexico

1

Spain

1

Moldova, Republic of

1

Denmark

1

RS

1

Poland

1

Croatia

1

Portugal

1

Taiwan

1

Lithuania

1

Slovenia

1

Hungary

37. List of Nuplazid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517860 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(13 years from now)

US10953000 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(13 years from now)

Do you want to check out NUPLAZID patents from before 2022?

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis

Dosage: TABLET;ORAL

How can I launch a generic of NUPLAZID before it's patent expiration?
More Information on Dosage

NUPLAZID family patents

8

United States

1

Sweden

38. List of Nuzyra drug patents

Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof
Aug, 2037

(14 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

Do you want to check out NUZYRA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 2027-10-03

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia

Dosage: TABLET;ORAL

More Information on Dosage

NUZYRA family patents

15

United States

4

Singapore

3

Taiwan

3

Australia

2

China

2

Russia

2

Philippines

2

Brazil

2

Canada

2

Mexico

2

Japan

2

European Union

39. List of Orgovyx drug patents

ORGOVYX's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786501 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US10449191 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US11583526 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

Do you want to check out ORGOVYX patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORGOVYX family patents

16

United States

7

European Union

4

Japan

4

Australia

3

Canada

3

Morocco

3

Argentina

EA

3

EA

3

Israel

2

China

2

Brazil

2

New Zealand

2

Mexico

1

Spain

1

Moldova, Republic of

1

Denmark

1

RS

1

Poland

1

Croatia

1

Portugal

1

Taiwan

1

Lithuania

1

Slovenia

1

Hungary

40. List of Otiprio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040004 ALK ABELLO Otic gel formulations for treating otitis externa
Nov, 2037

(14 years from now)

Do you want to check out OTIPRIO patents from before 2022?

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage

OTIPRIO family patents

4

United States

1

European Union

41. List of Oxbryta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Oct, 2037

(14 years from now)

Do you want to check out OXBRYTA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 25, 2026
New Chemical Entity Exclusivity (NCE) Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 2023-11-26

Market Authorisation Date: 25 November, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

OXBRYTA family patents

7

United States

2

Israel

1

Brazil

1

Taiwan

1

Morocco

1

Argentina

1

Mexico

1

European Union

42. List of Pizensy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806743 BRAINTREE LABS Method of administering lactitol to reduce plasma concentration of lactitol
May, 2037

(13 years from now)

Do you want to check out PIZENSY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2025

Drugs and Companies using LACTITOL ingredient

NCE-1 date: 2024-02-13

Market Authorisation Date: 12 February, 2020

Treatment: Method of treating chronic idiopathic constipation in adult patients.

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

43. List of Procysbi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328037

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(13 years from now)

US10548859

(Pediatric)

HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Feb, 2037

(13 years from now)

US10143665

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(13 years from now)

US10905662

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(13 years from now)

Do you want to check out PROCYSBI patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 22, 2024
Pediatric Exclusivity (PED) Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 30 April, 2013

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's patent expiration?
More Information on Dosage

44. List of Pylarify drug patents

Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(14 years from now)

Do you want to check out PYLARIFY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 2025-05-26

Market Authorisation Date: 26 May, 2021

Treatment: Method of positron emission tomography (pet) in men with prostate cancer

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PYLARIFY family patents

5

United States

2

Japan

1

Korea, Republic of

1

China

1

Canada

1

Singapore

1

European Union

45. List of Retevmo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112942 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10172851 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

US10137124 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

Do you want to check out RETEVMO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 8, 2025
Orphan Drug Exclusivity (ODE) Sep 21, 2029

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: 2024-05-08

Market Authorisation Date: 08 May, 2020

Treatment: Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant m...

Dosage: CAPSULE;ORAL

More Information on Dosage

RETEVMO family patents

12

United States

4

Japan

2

China

2

Morocco

2

Israel

2

European Union

1

Spain

1

Dominican Republic

1

Philippines

1

Moldova, Republic of

1

Denmark

1

RS

1

Poland

1

Brazil

1

Canada

1

Ukraine

1

Singapore

1

Argentina

EA

1

EA

1

Croatia

1

Korea, Republic of

1

Peru

1

Chile

1

Portugal

1

Taiwan

1

Jordan

1

Mexico

1

Australia

1

Costa Rica

1

Ecuador

1

Colombia

1

Lithuania

1

Saudi Arabia

1

Tunisia

1

Slovenia

1

Hungary

46. List of Reyvow drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(14 years from now)

Do you want to check out REYVOW patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: 2024-02-01

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage

REYVOW family patents

3

United States

3

China

2

Japan

2

Korea, Republic of

1

Spain

1

Dominican Republic

1

Philippines

1

Moldova, Republic of

1

Denmark

1

RS

1

Poland

1

Brazil

1

Canada

1

Ukraine

1

Morocco

EA

1

EA

1

New Zealand

1

Croatia

1

Peru

1

Israel

1

Chile

1

Portugal

1

Taiwan

1

Jordan

1

Mexico

1

Australia

1

Costa Rica

1

Ecuador

1

South Africa

1

Colombia

1

Lithuania

1

Tunisia

1

Slovenia

1

Hungary

1

European Union

47. List of Rozlytrek drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(13 years from now)

Do you want to check out ROZLYTREK patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2026
New Chemical Entity Exclusivity (NCE) Aug 15, 2024

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 2023-08-16

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotr...

Dosage: CAPSULE;ORAL

More Information on Dosage

ROZLYTREK family patents

4

United States

3

European Union

2

Japan

1

Korea, Republic of

1

Poland

1

China

1

Spain

1

Hong Kong

1

Israel

1

Canada

1

Brazil

1

Mexico

1

Australia

48. List of Saxenda drug patents

SAXENDA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(13 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(14 years from now)

Do you want to check out SAXENDA patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's patent expiration?
More Information on Dosage

SAXENDA family patents

5

European Union

2

United States

1

Spain

1

Philippines

1

Denmark

1

RS

1

Poland

1

China

1

Russia

1

Brazil

1

Canada

1

Morocco

1

Japan

1

Croatia

1

Korea, Republic of

1

Israel

1

Chile

1

Portugal

1

Mexico

1

Australia

1

South Africa

1

Slovenia

1

Hungary

49. List of Sunlenca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10071985 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10654827 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(14 years from now)

Do you want to check out SUNLENCA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2027

Drugs and Companies using LENACAPAVIR SODIUM ingredient

NCE-1 date: 2026-12-22

Market Authorisation Date: 22 December, 2022

Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

50. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

Do you want to check out SUNOSI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

SUNOSI family patents

6

United States

1

Korea, Republic of

1

China

1

Russia

1

Philippines

1

Chile

1

Israel

1

Canada

1

Singapore

1

Mexico

1

Japan

1

Australia

1

Denmark

1

European Union

51. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512609 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10195151 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

Do you want to check out SUNOSI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)

Dosage: TABLET;ORAL

More Information on Dosage

SUNOSI family patents

6

United States

1

Korea, Republic of

1

China

1

Russia

1

Philippines

1

Chile

1

Israel

1

Canada

1

Singapore

1

Mexico

1

Japan

1

Australia

1

Denmark

1

European Union

52. List of Sutab drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11382864 BRAINTREE LABS Solid oral sulfate salt formulations for cleansing a colon and methods of using same
Aug, 2037

(14 years from now)

US10143656 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(14 years from now)

US11033498 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(14 years from now)

Do you want to check out SUTAB patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Nov 10, 2023

Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 10 November, 2020

Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy

Dosage: TABLET;ORAL

More Information on Dosage

SUTAB family patents

4

United States

53. List of Tirosint-sol drug patents

TIROSINT-SOL's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11096913 INSTITUT BIOCHIMIQUE High-stability packaged solutions of T4 thyroid hormone
Feb, 2037

(13 years from now)

US10537538 INSTITUT BIOCHIMIQUE High-stability packaged solutions of T4 thyroid hormone
Feb, 2037

(13 years from now)

Do you want to check out TIROSINT-SOL patents from before 2022?

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 15 December, 2016

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of TIROSINT-SOL before it's patent expiration?
More Information on Dosage

TIROSINT-SOL family patents

3

United States

3

European Union

1

Poland

1

Russia

1

Spain

1

China

1

Canada

1

Portugal

1

Denmark

1

Slovenia

1

Hungary

54. List of Tlando drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559530 ANTARES PHARMA INC Oral testosterone undecanoate therapy
Nov, 2037

(14 years from now)

Do you want to check out TLANDO patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: CAPSULE;ORAL

More Information on Dosage

55. List of Trikafta (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11453655 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(14 years from now)

US10793547 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517564 VERTEX PHARMS INC Methods of treatment for cystic fibrosis
Dec, 2037

(14 years from now)

US11179367 VERTEX PHARMS INC Pharmaceutical compositions for treating cystic fibrosis
Dec, 2037

(14 years from now)

Do you want to check out TRIKAFTA (COPACKAGED) patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 8, 2024
New Chemical Entity Exclusivity (NCE) Oct 21, 2024
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 2023-10-22

Market Authorisation Date: 21 October, 2019

Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering daily e...

Dosage: TABLET;ORAL

More Information on Dosage

TRIKAFTA (COPACKAGED) family patents

16

United States

5

Israel

4

Morocco

4

Australia

4

European Union

3

Brazil

3

Canada

EA

3

EA

3

Japan

2

Uruguay

2

China

2

Argentina

2

Chile

2

Taiwan

2

Mexico

2

Colombia

1

Spain

1

Moldova, Republic of

1

Denmark

1

RS

1

Russia

1

Singapore

1

Croatia

1

Korea, Republic of

1

Peru

1

Portugal

1

Jordan

1

Ecuador

1

South Africa

1

Lithuania

1

Saudi Arabia

1

Slovenia

1

Hungary

56. List of Victoza drug patents

VICTOZA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jan, 2037

(13 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jul, 2037

(14 years from now)

Do you want to check out VICTOZA patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 17, 2022
Pediatric Exclusivity (PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 25 January, 2010

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of VICTOZA before it's patent expiration?
More Information on Dosage

VICTOZA family patents

5

European Union

2

United States

1

Spain

1

Philippines

1

Denmark

1

RS

1

Poland

1

China

1

Russia

1

Brazil

1

Canada

1

Morocco

1

Japan

1

Croatia

1

Korea, Republic of

1

Israel

1

Chile

1

Portugal

1

Mexico

1

Australia

1

South Africa

1

Slovenia

1

Hungary

57. List of Vitrakvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(13 years from now)

US11191766 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(13 years from now)

US11484535 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(13 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(13 years from now)

US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(13 years from now)

Do you want to check out VITRAKVI patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 26, 2025
New Chemical Entity Exclusivity (NCE) Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: 2022-11-26

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution; Method of treating...

Dosage: SOLUTION;ORAL

More Information on Dosage

VITRAKVI family patents

16

United States

4

Chile

3

Morocco

3

Korea, Republic of

3

Tunisia

2

Philippines

2

Russia

2

China

2

Brazil

2

Canada

2

Ukraine

2

Singapore

2

Japan

2

Israel

2

Mexico

2

European Union

1

Dominican Republic

1

Argentina

1

Nicaragua

1

Peru

1

Taiwan

1

Georgia

1

Australia

1

Cuba

1

Costa Rica